Intervention

polymorphism analysis

ClinicalTrials.gov intervention label

Explore related research

Search across original and mapped records

Search results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 44 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials44

Recruiting0

Common conditions25

Lead sponsors shown15

Clinical trials

44 shown

Study of ABCB1,SLC22A16 Drug Transporter Genes and Doxorubicin and Cyclophosphamide Toxicity in Brest Cancer PatientNCT04654195 · 2020-12-01

Study of CYP2C19 and ALDH3A1 Polymorphisms in Breast Cancer PatientsNCT04581967 · 2020-10-15

Collecting and Studying Tissue Samples From Patients With HIV-Associated MalignanciesNCT01567722 · 2013-01-02

Study of Tissue Samples From Patients With Non-Small Cell Lung CancerNCT01414595 · 2012-03-01

Biomarkers in Tissue Samples From Patients With Breast Cancer Treated With BevacizumabNCT01156168 · 2011-04-05

Study of Changes in Estrogen Levels and Grip Strength in Postmenopausal Women Who Have Received 4 to 6 Years of Hormone Therapy for Breast Cancer and Are Currently Receiving Letrozole on Clinical Trial IBCSG-35-07NCT01281137 · 2011-01-01

S9346A Blood Samples From Patients With Metastatic Prostate Cancer Previously Treated With Bicalutamide and GoserelinNCT01120262 · 2010-02-01

Riluzole in Women With Stage I, Stage II, or Stage IIIA Breast CancerNCT00903214 · 2009-05-01

Study of Blood Samples From High-Risk Postmenopausal Women Who Received Treatment on Breast Cancer Prevention Clinical Trials NSABP-P-1 or NSABP-P-2NCT00967239 · 2009-04-01

Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for CancerNCT00949052 · 2009-01-01

Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to ChemotherapyNCT01083368 · 2009-01-01

Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell TransplantNCT00957736 · 2008-11-01

Cancer Genome Study Using Samples From Patients With Stage I or Stage II Non-Small Cell Lung Cancer Treated on Clinical Trial ACOSOG-Z0030NCT00899535 · 2008-10-01

Study of Tumor and Blood Samples From Postmenopausal Women With Primary Breast Cancer Enrolled on Clinical Trial CAN-NCIC-MA27NCT00968214 · 2008-09-01

Study of Tissue and Blood Samples From Patients With Recurrent Prostate Cancer Who Received Lapatinib on Clinical Trial ECOG-E5803NCT00897351 · 2008-07-10

Studying Genes, Environment, and Prostate Cancer Risk in Patients With or Without Prostate CancerNCT01013129 · 2008-07-01

Study of Biomarkers in Blood and/or Tumor Tissue Samples From Patients With Ductal Carcinoma in Situ and From Healthy VolunteersNCT00935233 · 2008-07-01

Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and TrastuzumabNCT00875238 · 2008-06-01

Studying Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation CarriersNCT00897455 · 2008-04-01

Study of Blood and Tissue Samples From Patients With Locally Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Treated With Bevacizumab, Carboplatin, and PaclitaxelNCT00900172 · 2008-03-15

Study of Genes and Environment in Patients With Breast Cancer in the East Anglia Region of the United KingdomNCT00757211 · 2008-02-01

Study of Genes and the Environment in Patients With Prostate Cancer Residing in the East Anglia, Trent, or West Midlands Regions of the United KingdomNCT00758173 · 2008-02-01

Changes in Breast Density and Blood Hormone Levels in Postmenopausal Women Receiving Anastrozole or Exemestane for Breast CancerNCT00516698 · 2007-09-01

Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerNCT01557959 · 2007-07-01

Genetics of Women With Lobular Carcinoma in Situ of the BreastNCT00536718 · 2007-06-01

Development of a Model to Predict Progression-Free Survival After Erlotinib in Patients With Non-Small Cell Lung CancerNCT00897533 · 2007-04-13

Collecting and Storing Tissue and DNA Samples From Patients Undergoing a Donor Stem Cell TransplantNCT00900406 · 2007-01-01

SWOG 8897-A DNA Analysis in Predicting Treatment Outcome in Women With Breast Cancer in SWOG 8897NCT00896623 · 2006-12-01

Tumor Response to Pemetrexed Disodium in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Enrolled in Clinical Trial MCCRC-RC0524NCT00898820 · 2006-11-01

Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate CancerNCT01338792 · 2006-06-01

DNA Changes in Patients With Prostate CancerNCT00899184 · 2006-05-23

Trastuzumab for 6 Months or 1 Year in Treating Women With Nonmetastatic Breast Cancer That Can Be Removed By SurgeryNCT00381901 · 2006-05-01

Studying Tumor Tissue Samples to Learn More About DNA Changes and Response in Patients With Breast Cancer Treated With Bevacizumab on Clinical Trial ECOG-2100NCT00899418 · 2006-05-01

Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological CancerNCT00601406 · 2006-03-01

Studying Patterns, Causes, and Control of Disease in Patients With Lung Cancer in the North Trent (England) RegionNCT00693836 · 2006-01-01

S0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung CancerNCT00450281 · 2005-10-01

Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate CancerNCT00089609 · 2005-04-19

Genes That Affect Disease Progression in Women With Newly Diagnosed or Metastatic Breast CancerNCT00463034 · 2005-04-01

Dietary Phytoestrogens, Complementary and Alternative Medicine, and Lifestyle in Predicting Survival of Women With Breast CancerNCT00691509 · 2005-01-01

Genes and Other Risk Factors for Second Primary Breast Cancer in Women With Breast Cancer and Their Female Family Members and FriendsNCT00896818 · 2005-01-01

Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by SurgeryNCT00665457 · 2004-04-15

Studying Urine and Blood Samples in Women With Newly Diagnosed Breast CancerNCT00766454 · 1998-11-01

Study of a Polymorphism in Patients With Prostate CancerNCT00900185

Studying Biological Markers of Fatigue in Women With Residual Invasive Breast Cancer Enrolled on Clinical Trial NSABP-B-45NCT00914043

Common conditions

Mapped diseases appearing in these trials

Shared study participation does not establish that this intervention treats a disease.

Leading sponsors

ECOG-ACRIN Cancer Research Group 5 Alliance for Clinical Trials in Oncology 4 Cancer Research UK 3 SWOG Cancer Research Network 3 Vanderbilt-Ingram Cancer Center 3 Damanhour University 2 National Cancer Institute (NCI) 2 NSABP Foundation Inc 2 Wake Forest University Health Sciences 2 AIDS Malignancy Consortium 1 Barbara Ann Karmanos Cancer Institute 1 Cancer Research Centre at Weston Park Hospital 1 Case Comprehensive Cancer Center 1 Eastern Cooperative Oncology Group 1 ETOP IBCSG Partners Foundation 1

Trial status mix

COMPLETED25

UNKNOWN13

TERMINATED4

WITHDRAWN2

Phase mix

PHASE25

PHASE12

NA1

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.